Skip to main content
Top
Published in: Cancer Immunology, Immunotherapy 5/2017

01-05-2017 | Original Article

Differences in the frequencies of HLA-class I and II alleles between German patients with renal cell carcinoma and healthy controls

Authors: Steffen Goebel, Astrid Kehlen, Karen Bluemke, Wolfgang Altermann, Gerald Schlaf, Kersten Fischer, Paolo Fornara, Bernd Wullich, Sven Wach, Helge Taubert

Published in: Cancer Immunology, Immunotherapy | Issue 5/2017

Login to get access

Abstract

The human leukocyte antigen (HLA) system is a major part of the human immune system and has an impact on tumor initiation, tumor progression, and immunosurveillance. Renal cell carcinoma tumors are considered to be immunogenic. Therefore, we studied the allele frequencies of four gene loci (HLA-A, -B, -C, and HLA-DR) in a cohort of German renal cell carcinoma (RCC) patients and in healthy controls. HLA-A-C were determined using serological methods, whereas HLA-C12, C14, C16, C18, and HLA-DR were characterized through the use of standard molecular biological methods. The occurrence of the HLA-C*12 allele was significantly increased in German RCC patients compared with healthy controls (P < 0.005; Fisher’s exact test), whereas the occurrence of the HLA-DRB1*04 allele was significantly reduced in RCC patients compared with healthy controls (P < 0.05; Fisher’s exact test). However, the presence of allele HLA-C*12 was not significantly associated with 10 year overall survival. We suggest that the frequency of HLA alleles can affect development of RCC and could add knowledge as predictive marker for future immunotherapies.
Literature
1.
go back to reference Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136(5):E359–E386. doi:10.1002/ijc.29210 CrossRefPubMed Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136(5):E359–E386. doi:10.​1002/​ijc.​29210 CrossRefPubMed
2.
go back to reference Finke JH, Rayman P, Alexander J, Edinger M, Tubbs RR, Connelly R, Pontes E, Bukowski R (1990) Characterization of the cytolytic activity of CD4+ and CD8+ tumorinfiltrating lymphocytes in human renal cell carcinoma. Cancer Res 50(8):2363–2370PubMed Finke JH, Rayman P, Alexander J, Edinger M, Tubbs RR, Connelly R, Pontes E, Bukowski R (1990) Characterization of the cytolytic activity of CD4+ and CD8+ tumorinfiltrating lymphocytes in human renal cell carcinoma. Cancer Res 50(8):2363–2370PubMed
3.
4.
go back to reference Brasanac D, Müller CA, Müller GA, Hadzi-Dzokic J, Markovic-Lipkovski J (1999) HLA class I antigens expression in renal cell carcinoma: histopathological and clinical correlation. J Exp Clin Cancer Res 18(4):505–510PubMed Brasanac D, Müller CA, Müller GA, Hadzi-Dzokic J, Markovic-Lipkovski J (1999) HLA class I antigens expression in renal cell carcinoma: histopathological and clinical correlation. J Exp Clin Cancer Res 18(4):505–510PubMed
5.
go back to reference Brasanac D, Marković-Lipkovski J, Hadzi-Djokić J, Müller GA, Müller CA (1999) Immunohistochemical analysis of HLA class II antigens and tumor infiltrating mononuclear cells in renal cell carcinoma: correlation with clinical and histopathological data. Neoplasma 46(3):173–178PubMed Brasanac D, Marković-Lipkovski J, Hadzi-Djokić J, Müller GA, Müller CA (1999) Immunohistochemical analysis of HLA class II antigens and tumor infiltrating mononuclear cells in renal cell carcinoma: correlation with clinical and histopathological data. Neoplasma 46(3):173–178PubMed
7.
go back to reference Kantor AF, McLaughlin JK, Blattner WA, Bach FH, Blot WJ, Schuman LM, Fraumeni JF (1983) HLA antigens in renal cell carcinoma. Cancer Res 43(5):2330–2333PubMed Kantor AF, McLaughlin JK, Blattner WA, Bach FH, Blot WJ, Schuman LM, Fraumeni JF (1983) HLA antigens in renal cell carcinoma. Cancer Res 43(5):2330–2333PubMed
8.
go back to reference Rukstalis DB, Bubley GJ, Donahue JP, Richie JP, Seidman JG, DeWolf WC (1989) Regional loss of chromosome 6 in two urological malignancies. Cancer Res 49(18):5087–5090PubMed Rukstalis DB, Bubley GJ, Donahue JP, Richie JP, Seidman JG, DeWolf WC (1989) Regional loss of chromosome 6 in two urological malignancies. Cancer Res 49(18):5087–5090PubMed
9.
go back to reference Onishi T, Ohishi Y, Iizuka N, Imagawa K (1996) Phenotype frequency of human leukocyte antigens in Japanese patients with renal cell carcinoma who responded to interferon-alpha treatment. Int J Urol 3(6):435–440CrossRefPubMed Onishi T, Ohishi Y, Iizuka N, Imagawa K (1996) Phenotype frequency of human leukocyte antigens in Japanese patients with renal cell carcinoma who responded to interferon-alpha treatment. Int J Urol 3(6):435–440CrossRefPubMed
10.
go back to reference Ozdemir E, Kakehi Y, Nakamura E, Kinoshita H, Terachi T, Okada Y, Yoshida O (1997) HLA-DRB1*0101 and *0405 as protective alleles in Japanese patients with renal cell carcinoma. Cancer Res 57(4):742–746PubMed Ozdemir E, Kakehi Y, Nakamura E, Kinoshita H, Terachi T, Okada Y, Yoshida O (1997) HLA-DRB1*0101 and *0405 as protective alleles in Japanese patients with renal cell carcinoma. Cancer Res 57(4):742–746PubMed
11.
go back to reference Yilmaz E, Çekmen A, Akkuş E, Önal B, Özalp AU, Solok V, Erdoğan E, Eren B (2010) The relationship between human leukocyte antigens (HLA) and renal cell carcinoma. Bosn J Basic Med Sci 10(4):282–286PubMed Yilmaz E, Çekmen A, Akkuş E, Önal B, Özalp AU, Solok V, Erdoğan E, Eren B (2010) The relationship between human leukocyte antigens (HLA) and renal cell carcinoma. Bosn J Basic Med Sci 10(4):282–286PubMed
12.
go back to reference Ozgur BC, Gonenc F, Yazicioglu AH (2009) HLA class I and II antigens expression in patients with renal cell carcinoma. Saudi J Kidney Dis Transpl 20(1):97–101PubMed Ozgur BC, Gonenc F, Yazicioglu AH (2009) HLA class I and II antigens expression in patients with renal cell carcinoma. Saudi J Kidney Dis Transpl 20(1):97–101PubMed
13.
go back to reference Miller SA, Dykes DD, Polesky HF (1988) A simple salting out method procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16(3):1215CrossRefPubMedPubMedCentral Miller SA, Dykes DD, Polesky HF (1988) A simple salting out method procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16(3):1215CrossRefPubMedPubMedCentral
14.
go back to reference Al Omar S, Middleton D, Marshall E, Porter D, Xinarianos G, Raji O, Field JK, Christmas SE (2010 Oct) Associations between genes for killer immunoglobulin-like receptors and their ligands in patients with solid tumors. Hum Immunol 71(10):976–981. doi:10.1016/j.humimm.2010.06.019 CrossRefPubMed Al Omar S, Middleton D, Marshall E, Porter D, Xinarianos G, Raji O, Field JK, Christmas SE (2010 Oct) Associations between genes for killer immunoglobulin-like receptors and their ligands in patients with solid tumors. Hum Immunol 71(10):976–981. doi:10.​1016/​j.​humimm.​2010.​06.​019 CrossRefPubMed
15.
go back to reference Frohn C, Doehn C, Durek C, Böhle A, Schlenke P, Jocham D, Kirchner H (2000) Feasibility of the adoptive transfusion of allogenic human leukocyte antigen-matched natural killer cells in patients with renal cell carcinoma. J Immunother 23(4):499–504CrossRefPubMed Frohn C, Doehn C, Durek C, Böhle A, Schlenke P, Jocham D, Kirchner H (2000) Feasibility of the adoptive transfusion of allogenic human leukocyte antigen-matched natural killer cells in patients with renal cell carcinoma. J Immunother 23(4):499–504CrossRefPubMed
16.
go back to reference Igarashi T, Wynberg J, Srinivasan R, Becknell B, McCoy JP Jr, Takahashi Y, Suffredini DA, Linehan WM, Caligiuri MA, Childs RW (2004) Enhanced cytotoxicity of allogeneic NK cells with killer immunoglobulin-like receptor ligand incompatibility against melanoma and renal cell carcinoma cells. Blood 104(1):170–177CrossRefPubMed Igarashi T, Wynberg J, Srinivasan R, Becknell B, McCoy JP Jr, Takahashi Y, Suffredini DA, Linehan WM, Caligiuri MA, Childs RW (2004) Enhanced cytotoxicity of allogeneic NK cells with killer immunoglobulin-like receptor ligand incompatibility against melanoma and renal cell carcinoma cells. Blood 104(1):170–177CrossRefPubMed
18.
go back to reference Goodyear OC, Pearce H, Pratt G, Moss P (2011 Dec) Dominant responses with conservation of T-cell receptor usage in the CD8+ T-cell recognition of a cancer testis antigen peptide presented through HLA-Cw7 in patients with multiple myeloma. Cancer Immunol Immunother 60(12):1751–1761. doi:10.1007/s00262-011-1070-y CrossRefPubMed Goodyear OC, Pearce H, Pratt G, Moss P (2011 Dec) Dominant responses with conservation of T-cell receptor usage in the CD8+ T-cell recognition of a cancer testis antigen peptide presented through HLA-Cw7 in patients with multiple myeloma. Cancer Immunol Immunother 60(12):1751–1761. doi:10.​1007/​s00262-011-1070-y CrossRefPubMed
19.
go back to reference Ellerhorst JA, Hildebrand WH, Cavett JW, Fernandez-Vina MA, Hodges S, Poindexter N, Fischer H, Grimm EA (2004) HLA class II haplotypes predict favorable outcomes for patients with metastatic RCC. Urologe A 43(Suppl 3):S137CrossRefPubMed Ellerhorst JA, Hildebrand WH, Cavett JW, Fernandez-Vina MA, Hodges S, Poindexter N, Fischer H, Grimm EA (2004) HLA class II haplotypes predict favorable outcomes for patients with metastatic RCC. Urologe A 43(Suppl 3):S137CrossRefPubMed
20.
go back to reference Maker AV, Attia P, Rosenberg SA (2005) Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade. J Immunol 175(11):7746–7754CrossRefPubMedPubMedCentral Maker AV, Attia P, Rosenberg SA (2005) Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade. J Immunol 175(11):7746–7754CrossRefPubMedPubMedCentral
21.
go back to reference Pérez Ramírez S, Parra V, Avilés Izquierdo JA, Vicario JL, Martín M, Márquez-Rodas I (2014) Metastatic melanoma with spontaneous regression, psoriasis and HLA-Cw6: case report and a hypothesis to explore. Tumori 100(4):144e-147e. doi:10.1700/1636.17932 PubMed Pérez Ramírez S, Parra V, Avilés Izquierdo JA, Vicario JL, Martín M, Márquez-Rodas I (2014) Metastatic melanoma with spontaneous regression, psoriasis and HLA-Cw6: case report and a hypothesis to explore. Tumori 100(4):144e-147e. doi:10.​1700/​1636.​17932 PubMed
24.
go back to reference Massari F, Santoni M, Ciccarese C, Santini D, Alfieri S, Martignoni G, Brunelli M, Piva F, Berardi R, Montironi R, Porta C, Cascinu S, Tortora G (2015) PD-1 blockade therapy in renal cell carcinoma: current studies and future promises. Cancer Treat Rev 41:114–121. doi:10.1016/j.ctrv.2014.12.013 CrossRefPubMed Massari F, Santoni M, Ciccarese C, Santini D, Alfieri S, Martignoni G, Brunelli M, Piva F, Berardi R, Montironi R, Porta C, Cascinu S, Tortora G (2015) PD-1 blockade therapy in renal cell carcinoma: current studies and future promises. Cancer Treat Rev 41:114–121. doi:10.​1016/​j.​ctrv.​2014.​12.​013 CrossRefPubMed
25.
go back to reference Callea M, Albiges L, Gupta M, Cheng SC, Genega EM, Fay AP, Song J, Carvo I, Bhatt RS, Atkins MB, Hodi FS, Choueiri TK, McDermott DF, Freeman GJ, Signoretti S (2015) Differential expression of PD-L1 between primary and metastatic sites in clear cell Renal Cell Carcinoma. Cancer. Immunol Res 3(10):1158–1164. doi:10.1158/2326-6066.CIR-15-0043 Callea M, Albiges L, Gupta M, Cheng SC, Genega EM, Fay AP, Song J, Carvo I, Bhatt RS, Atkins MB, Hodi FS, Choueiri TK, McDermott DF, Freeman GJ, Signoretti S (2015) Differential expression of PD-L1 between primary and metastatic sites in clear cell Renal Cell Carcinoma. Cancer. Immunol Res 3(10):1158–1164. doi:10.​1158/​2326-6066.​CIR-15-0043
26.
go back to reference Kostine M, Cleven AH, de Miranda NF, Italiano A, Cleton-Jansen AM, Bovée JV (2016) Analysis of PD-L1, T-cell infiltrate and HLA expression in chondrosarcoma indicates potential for response to immunotherapy specifically in the dedifferentiated subtype. Mod Pathol 29(9):1028–1037. doi:10.1038/modpathol.2016.108 CrossRefPubMed Kostine M, Cleven AH, de Miranda NF, Italiano A, Cleton-Jansen AM, Bovée JV (2016) Analysis of PD-L1, T-cell infiltrate and HLA expression in chondrosarcoma indicates potential for response to immunotherapy specifically in the dedifferentiated subtype. Mod Pathol 29(9):1028–1037. doi:10.​1038/​modpathol.​2016.​108 CrossRefPubMed
27.
go back to reference Kitamura H, Honma I, Torigoe T, Asanuma H, Sato N, Tsukamoto T (2007) Down-regulation of HLA class I antigen is an independent prognostic factor for clear cell renal cell carcinoma. J Urol 177(4):1269–1272CrossRefPubMed Kitamura H, Honma I, Torigoe T, Asanuma H, Sato N, Tsukamoto T (2007) Down-regulation of HLA class I antigen is an independent prognostic factor for clear cell renal cell carcinoma. J Urol 177(4):1269–1272CrossRefPubMed
28.
29.
go back to reference Dengjel J, Nastke MD, Gouttefangeas C, Gitsioudis G, Schoor O, Altenberend F, Müller M, Krämer B, Missiou A, Sauter M, Hennenlotter J, Wernet D, Stenzl A, Rammensee HG, Klingel K, Stevanović S (2006) Unexpected abundance of HLA class II presented peptides in primary renal cell carcinomas. Clin Cancer Res 12(14 Pt 1):4163–4170CrossRefPubMed Dengjel J, Nastke MD, Gouttefangeas C, Gitsioudis G, Schoor O, Altenberend F, Müller M, Krämer B, Missiou A, Sauter M, Hennenlotter J, Wernet D, Stenzl A, Rammensee HG, Klingel K, Stevanović S (2006) Unexpected abundance of HLA class II presented peptides in primary renal cell carcinomas. Clin Cancer Res 12(14 Pt 1):4163–4170CrossRefPubMed
Metadata
Title
Differences in the frequencies of HLA-class I and II alleles between German patients with renal cell carcinoma and healthy controls
Authors
Steffen Goebel
Astrid Kehlen
Karen Bluemke
Wolfgang Altermann
Gerald Schlaf
Kersten Fischer
Paolo Fornara
Bernd Wullich
Sven Wach
Helge Taubert
Publication date
01-05-2017
Publisher
Springer Berlin Heidelberg
Published in
Cancer Immunology, Immunotherapy / Issue 5/2017
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-017-1957-3

Other articles of this Issue 5/2017

Cancer Immunology, Immunotherapy 5/2017 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine